| NVO | Novo Nordisk AS ADR | 9.76% |
| LLY | Eli Lilly and Co | 9.26% |
| SRRK | Scholar Rock Holding Corp | 5.71% |
| HIMS | Hims & Hers Health Inc Ordinary Shares - Class A | 5.57% |
| VKTX | Viking Therapeutics Inc | 5.49% |
| ABBV | AbbVie Inc | 5.20% |
| ARWR | Arrowhead Pharmaceuticals Inc | 5.08% |
| 1801.HK | Innovent Biologics Inc | 5.00% |
| AMGN | Amgen Inc | 4.58% |
| 4519.T | Chugai Pharmaceutical Co Ltd | 4.57% |
No recent news for THNR. The ingest cron pulls every 15 minutes during market hours.
THNR provides access to global companies expected to economically benefit from weight loss drug development. THNR seeks investment results that generally correspond to the performance (before fees and expenses) of the VettaFi Weight Loss Drug & Treatment Index.
Amplify Weight Loss Drug & Treatment ETF · Issued by Amplify